Skip to main content
main-content

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

Erschienen in: memo - Magazine of European Medical Oncology 2/2021

01.06.2021 | editorial

Immunotherapy revisited

verfasst von: Assoc. Prof. PD Dr. Thorsten Füreder

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 2/2021

Einloggen, um Zugang zu erhalten
share
TEILEN

Excerpt

Immunotherapy has revolutionized cancer treatment during the last few years. Impressive long-term survival rates (beyond 5 years) even in deadly diseases such as metastatic lung cancer or malignant melanoma were achieved by checkpoint inhibitor (CPI) therapy. …
Literatur
4.
Zurück zum Zitat Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Five-year survival with combined nivolumab and Ipilimumab in advanced melanoma. N Engl J Med. 2019;381:1535–46. CrossRef Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Five-year survival with combined nivolumab and Ipilimumab in advanced melanoma. N Engl J Med. 2019;381:1535–46. CrossRef
6.
Zurück zum Zitat Aguiar PN Jr., Santoro IL, Tadokoro H, et al. The role of PD-L1 expression as a predictive biomarker in advanced non-small-cell lung cancer: a network meta-analysis. Immunotherapy. 2016;8:479–88. CrossRef Aguiar PN Jr., Santoro IL, Tadokoro H, et al. The role of PD-L1 expression as a predictive biomarker in advanced non-small-cell lung cancer: a network meta-analysis. Immunotherapy. 2016;8:479–88. CrossRef
Metadaten
Titel
Immunotherapy revisited
verfasst von
Assoc. Prof. PD Dr. Thorsten Füreder
Publikationsdatum
01.06.2021
Verlag
Springer Vienna
Erschienen in
memo - Magazine of European Medical Oncology / Ausgabe 2/2021
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-021-00711-7